Alain Schoepfer

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


279 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | ...
 
Eosinophil Distribution in Eosinophilic Esophagitis and its Impact on Disease Activity and Response to Treatment.
Godat A., Mueller R., Schenker D., Schoepfer A.M., Straumann A., Greuter T., EoE eosinophil distribution research group Clinical gastroenterology and hepatology. Peer-reviewed.
 
A MULTICENTER LONG-TERM COHORT STUDY OF EOSINOPHILIC ESOPHAGITIS VARIANTS AND THEIR PROGRESSION TO EOE OVER TIME.
Greuter T., Straumann A., Fernandez-Marrero Y., Germic N., Hosseini A., Chanwangpong A., Yousefi S., Simon D., Collins M.H., Bussmann C. et al. Clinical and translational gastroenterology. Peer-reviewed.
 
Pediatric Patients with Eosinophilic Esophagitis and Their Parents Identify Symptoms as the Most Important Treatment Outcome.
von Graffenried T., Safroneeva E., Braegger C., Ezri J., Garzoni L., Giroud Rivier A., Greuter T., Köhler H., McLin V.A., Marx G. et al. International archives of allergy and immunology. Peer-reviewed.
 
Endoscopic Features of Eosinophilic Esophagitis.
Schoepfer A.M., Safroneeva E., Peterson K., 2024/05. Immunology and allergy clinics of North America, 44 (2) pp. 197-204. Peer-reviewed.
 
Gastroentérologie et hépatologie: ce qui a changé en 2023 [Gastroenterology and hepatology: what's new in 2023]
Fraga M., Wakim El-Khoury J., Oumrani S., Godat S., Vionnet J., Schoepfer A., Vieira Barbosa J., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 42-46. Peer-reviewed.
 
Histological Phenotyping in Eosinophilic Esophagitis: Localized Proximal Disease Is Infrequent but Associated with Less Severe Disease and Better Disease Outcome.
Heil A., Kuehlewindt T., Godat A., Simon H.U., Simon D., Schreiner P., Saner C., Vavricka S.R., Biedermann L., Safroneeva E. et al., 2024. International archives of allergy and immunology, 185 (1) pp. 63-72. Peer-reviewed.
 
Monitoring Patients With Eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations.
Arnim U.V., Biedermann L., Aceves S.S., Bonis P.A., Collins M.H., Dellon E.S., Furuta G.T., Gonsalves N., Gupta S., Hirano I. et al., 2023/09. Clinical gastroenterology and hepatology, 21 (10) pp. 2526-2533. Peer-reviewed.
 
Dyspepsie fonctionnelle : update 2023 [Functional dyspepsia : update 2023]
Voirol-Perrin J., Stamm G.M., Salvador Nunes L., Schoepfer A., 2023/08/30. Revue medicale suisse, 19 (839) pp. 1554-1557. Peer-reviewed.
Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice.
Rossier L., Matter C., Burri E., Galperine T., Hrúz P., Juillerat P., Schoepfer A., Vavricka S.R., Zahnd N., Décosterd N. et al., 2023/08/25. Swiss medical weekly, 153 p. 40100. Peer-reviewed.
 
Barrett's Esophagus in Eosinophilic Esophagitis in Swiss Eosinophilic Esophagitis Cohort Study (SEECS).
Scherer R., Schreiner P., Rossel J.B., Greuter T., Burri E., Saner C., Schlag C., Safroneeva E., Schoepfer A., Straumann A. et al., 2023/05. Digestive diseases, 41 (5) pp. 695-707. Peer-reviewed.
 
Efficacy and safety of endoscopic ultrasound guided drainage of pseudocysts and walled-off necrosis after failure of percutaneous drainage.
Mack S., Galasso D., Marx M., Robert M., Romailler E., Oumrani S.H., Aslan N., Moschouri E., Schoepfer A., Godat S., 2023/04. Surgical endoscopy, 37 (4) pp. 2626-2632. Peer-reviewed.
Häufige Magen-Darm-Beschwerden: Management der funktionellen Dyspepsie und des Reizdarm-Syndroms in der Praxis [Frequent Gastro-Intestinal Disorders: Management of Functional Dyspepsia and Irritable Bowel Syndrome in Clinical Practice]
Pohl D., Vavricka S., Fox M., Madisch A., Studerus D., Wiesel P., Heinrich H., Linas I., Schoepfer A., Schwizer A. et al., 2023/04. Praxis, 112 (5-6) pp. 304-316. Peer-reviewed.
 
Dupilumab in Patients with Eosinophilic Esophagitis.
Greuter T., Schoepfer A.M., 2023/03/09. The New England journal of medicine, 388 (10) pp. 955-956. Peer-reviewed.
External validation and comparison of the Glasgow-Blatchford score, modified Glasgow-Blatchford score, Rockall score and AIMS65 score in patients with upper gastrointestinal bleeding: a cross-sectional observational study in Western Switzerland.
Rivieri S., Carron P.N., Schoepfer A., Ageron F.X., 2023/02/01. European journal of emergency medicine, 30 (1) pp. 32-39. Peer-reviewed.
 
Gastroentérologie et hépatologie : ce qui a changé en 2022 [Gastroenterology and hepatology: what's new in 2022]
Fraga M., Ghaoui C., Stamm G.M., Schoepfer A., Greuter T., 2023/02/01. Revue medicale suisse, 19 (812) pp. 217-220. Peer-reviewed.
Preoperative hiatal hernia in esophageal adenocarcinoma; does it have an impact on patient outcomes?
St-Amour P., Mantziari S., Dromain C., Winiker M., Godat S., Schoepfer A., Demartines N., Schäfer M., 2023/02. Surgical oncology, 46 p. 101904. Peer-reviewed.
Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease.
Martinho-Grueber M., Kapoglou I., Bravo F., Sarraj R., Benz E., Restellini S., Biedermann L., Rogler G., Vavricka S.R., Schoepfer A. et al., 2023/01/01. European journal of gastroenterology & hepatology, 35 (1) pp. 21-30. Peer-reviewed.
Eosinophilic Esophagitis beyond Eosinophils - an Emerging Phenomenon Overlapping with Eosinophilic Esophagitis: Collegium Internationale Allergologicum (CIA) Update 2023.
Salvador Nunes V.S., Straumann A., Salvador Nunes L., Schoepfer A.M., Greuter T., 2023. International archives of allergy and immunology, 184 (5) pp. 411-420. Peer-reviewed.
Drug-Related Adverse Events Necessitating Treatment Discontinuation in Pediatric Inflammatory Bowel Disease Patients.
Salzmann M., von Graffenried T., Righini-Grunder F., Braegger C., Spalinger J., Schibli S., Schoepfer A., Nydegger A., Pittet V., Sokollik C. et al., 2022/12/01. Journal of pediatric gastroenterology and nutrition, 75 (6) pp. 731-736. Peer-reviewed.
 
Diagnostic Delay in Patients With Eosinophilic Esophagitis Has Not Changed Since the First Description 30 Years Ago: Diagnostic Delay in Eosinophilic Esophagitis.
Murray F.R., Kreienbuehl A.S., Greuter T., Nennstiel S., Safroneeva E., Saner C., Schindler V., Schlag C., Schoepfer A.M., Schreiner P. et al., 2022/11/01. The American journal of gastroenterology, 117 (11) pp. 1772-1779. Peer-reviewed.
Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial.
Dellon E.S., Lucendo A.J., Schlag C., Schoepfer A.M., Falk G.W., Eagle G., Nezamis J., Comer G.M., Knoop K., Hirano I., 2022/11. Clinical gastroenterology and hepatology, 20 (11) pp. 2485-2494.e15. Peer-reviewed.
 
International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature.
Dellon E.S., Gonsalves N., Abonia J.P., Alexander J.A., Arva N.C., Atkins D., Attwood S.E., Auth MKH, Bailey D.D., Biederman L. et al., 2022/11. Clinical gastroenterology and hepatology, 20 (11) pp. 2474-2484.e3. Peer-reviewed.
 
Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus Conference.
Aceves S.S., Alexander J.A., Baron T.H., Bredenoord A.J., Day L., Dellon E.S., Falk G.W., Furuta G.T., Gonsalves N., Hirano I. et al., 2022/10. Gastrointestinal endoscopy, 96 (4) pp. 576-592.e1. Peer-reviewed.
 
Management of eosinophilic esophagitis associated food impaction in Europe and the United States.
Schreiner P., Safroneeva E., Schoepfer A., Greuter T., Biedermann L., Schlag C., Labenz J., Auth MKH, Bredenoord A.J., Chang J.W. et al., 2022/09/14. Diseases of the esophagus, 35 (9) pp. doac003. Peer-reviewed.
 
Management of non-functional pancreatic neuroendocrine tumors by endoscopic ultrasound-guided radiofrequency ablation: Retrospective study in two tertiary centers.
Marx M., Godat S., Caillol F., Poizat F., Ratone J.P., Pesenti C., Schoepfer A., Hoibian S., Dahel Y., Giovannini M., 2022/09. Digestive endoscopy, 34 (6) pp. 1207-1213. Peer-reviewed.
Diagnostic différentiel et investigation de la diarrhée chronique [Differential diagnosis and investigation of chronic diarrhea]
Stamm G.M., Salvador Nunes L., Greuter T., Godat S., Schoepfer A., 2022/08/31. Revue medicale suisse, 18 (793) pp. 1578-1583. Peer-reviewed.
Métabolisme et suivi thérapeutique de l’azathioprine en gastroentérologie et hépatologie [Metabolism and therapeutic monitoring of azathioprine in gastroenterology and hepatology]
Bianchetti D., Salvador Nunes L., André P., Schoepfer A., Moradpour D., Chtioui H., 2022/08/31. Revue medicale suisse, 18 (793) pp. 1588-1593. Peer-reviewed.
Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multi-center study.
Greuter T., Straumann A., Fernandez-Marrero Y., Germic N., Hosseini A., Yousefi S., Simon D., Collins M.H., Bussmann C., Chehade M. et al., 2022/08. Allergy, 77 (8) pp. 2520-2533. Peer-reviewed.
 
Disease Burden and Unmet Need in Eosinophilic Esophagitis.
Bredenoord A.J., Patel K., Schoepfer A.M., Dellon E.S., Chehade M., Aceves S.S., Spergel J.M., Shumel B., Deniz Y., Rowe P.J. et al., 2022/08/01. The American journal of gastroenterology, 117 (8) pp. 1231-1241. Peer-reviewed.
 
Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis.
Schreiner P., Safroneeva E., Rossel J.B., Limacher A., Saner C., Greuter T., Schoepfer A., Straumann A., Biedermann L., 2022/08. Clinical gastroenterology and hepatology, 20 (8) pp. 1729-1738.e1. Peer-reviewed.
 
A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.
Dellon E.S., Khoury P., Muir A.B., Liacouras C.A., Safroneeva E., Atkins D., Collins M.H., Gonsalves N., Falk G.W., Spergel J.M. et al., 2022/07. Gastroenterology, 163 (1) pp. 59-76. Peer-reviewed.
 
A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.
Dellon E.S., Khoury P., Muir A.B., Liacouras C.A., Safroneeva E., Atkins D., Collins M.H., Gonsalves N., Falk G.W., Spergel J.M. et al., 2022/07. The Journal of allergy and clinical immunology, 150 (1) pp. 33-47. Peer-reviewed.
Impact of Diagnostic Delay on Disease Course in Pediatric- versus Adult-Onset Patients with Ulcerative Colitis: Data from the Swiss IBD Cohort.
Schoepfer A.M., Tran VDC, Rossel J.B., Sokollik C., Spalinger J., Safroneeva E., von Graffenried T., Godat S., Hahnloser D., Vavricka S.R. et al., 2022/07. Inflammatory intestinal diseases, 7 (2) pp. 87-96. Peer-reviewed.
Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study.
Bähler C., Brüngger B., Blozik E., Vavricka S.R., Schoepfer A.M., 2022/07. Inflammatory intestinal diseases, 7 (2) pp. 104-117. Peer-reviewed.
 
EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers.
Marx M., Trosic-Ivanisevic T., Caillol F., Demartines N., Schoepfer A., Pesenti C., Ratone J.P., Robert M., Giovannini M., Godat S., 2022/06. Gastrointestinal endoscopy, 95 (6) pp. 1256-1263. Peer-reviewed.
 
Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis.
Ma C., Bredenoord A.J., Dellon E.S., Alexander J.A., Biedermann L., Hogan M., Guizzetti L., Zou G., Katzka D.A., Chehade M. et al., 2022/06. Gastrointestinal endoscopy, 95 (6) pp. 1126-1137.e2. Peer-reviewed.
Méthodes diagnostiques non invasives de l'Helicobacter pylori
Raiss Rida, Koehli Lionel, Schoepfer Alain, Gouveia Alexandre, 2022/05/10. Forum Médical Suisse ‒ Swiss Medical Forum, 22 (1920). Peer-reviewed.
Impact of Overweight and Obesity on Disease Outcome in the Pediatric Swiss Inflammatory Bowel Disease Cohort.
von Graffenried T., Schoepfer A.M., Rossel J.B., Greuter T., Safroneeva E., Godat S., Henchoz S., Vavricka S.R., Sokollik C., Spalinger J. et al., 2022/05. JPGN reports, 3 (2) pp. e193. Peer-reviewed.
Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.
Miehlke S., Schlag C., Lucendo A.J., Biedermann L., Vaquero C.S., Schmoecker C., Hayat J., Hruz P., Ciriza de Los Rios C., Bredenoord A.J. et al., 2022/04. United European gastroenterology journal, 10 (3) pp. 330-343. Peer-reviewed.
Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis.
Bon L., Safroneeva E., Bussmann C., Biedermann L., Schreiner P., Vavricka S.R., Schoepfer A.M., McCright-Gill T., Simon H.U., Straumann A. et al., 2022/04. United European gastroenterology journal, 10 (3) pp. 308-318. Peer-reviewed.
 
Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis.
Safroneeva E., Pan Z., King E., Martin L.J., Collins M.H., Yang G.Y., Capocelli K.E., Arva N.C., Abonia J.P., Atkins D. et al., 2022/04. Clinical gastroenterology and hepatology, 20 (4) pp. 766-775.e4. Peer-reviewed.
Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS).
COREOS Collaborators:, Ma C., Schoepfer A.M., Dellon E.S., Bredenoord A.J., Chehade M., Collins M.H., Feagan B.G., Furuta G.T., Gupta S.K. et al., 2022/02. The Journal of allergy and clinical immunology, 149 (2) pp. 659-670. Peer-reviewed.
A Response to: Letter to the Editor Regarding 'Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland'.
Aksan A., Schoepfer A., Juillerat P., Vavricka S., Bettencourt M., Ramirez de Arellano A., Gavata S., Morin N., Valentine W.J., Hunt B., 2022/01. Advances in therapy, 39 (1) pp. 815-821. Peer-reviewed.
 
Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study.
Greuter T., Godat A., Ringel A., Almonte H.S., Schupack D., Mendoza G., McCright-Gill T., Dellon E.S., Hirano I., Alexander J. et al., 2021/12. Clinical gastroenterology and hepatology, 19 (12) pp. 2514-2523.e2. Peer-reviewed.
 
Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis.
Schoepfer A.M., Henchoz S., Biedermann L., Schreiner P., Greuter T., Reinhard A., Senn J., Franke A., Burri E., Juillerat P. et al., 2021/11. Gastrointestinal endoscopy, 94 (5) pp. 912-919.e2. Peer-reviewed.
Increasing Incidence of Microscopic Colitis in a Population-Based Cohort Study in Switzerland.
Maye H., Safroneeva E., Godat S., Sempoux C., Yan P., Bouzourène H., Seelentag W., Stauffer E., Taminelli L., Seibold F. et al., 2021/10. Clinical gastroenterology and hepatology, 19 (10) pp. 2205-2206. Peer-reviewed.
 
Higher educational level in patients with eosinophilic esophagitis: a comparative analysis.
Roth R., Safroneeva E., Saner Zilian C., Schreiner P., Rossel J.B., Bopp M., Greuter T., Scharl M., Pittet V., Rogler G. et al., 2021/09/09. Diseases of the esophagus, 34 (9) pp. doab010. Peer-reviewed.
 
A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus.
Ma C., Schoepfer A.M., Safroneeva E., COREOS Collaborators, 2021/09. Gastroenterology, 161 (3) pp. 778-784. Peer-reviewed.
Actualités en endoscopie digestive : trois procédures endoscopiques prometteuses [Novelties in digestive endoscopy: three promising endoscopic procedures]
Gfeller É., Romailler É., Ollo D., Robert M., Greuter T., Schoepfer A., Godat S., 2021/09/01. Revue medicale suisse, 17 (748) pp. 1443-1447. Peer-reviewed.
 
Body composition assessment in children with inflammatory bowel disease: A comparison of different methods.
von Graffenried T., Godin J.P., Schoepfer A., Breton I., Martin F.P., Nydegger A., 2021/09. Journal of paediatrics and child health, 57 (9) pp. 1414-1419. Peer-reviewed.
 
Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus.
Ma C., Schoepfer A.M., Safroneeva E., COREOS Collaborators, COREOS Collaborators, 2021/09. Gastroenterology, 161 (3) pp. 748-755. Peer-reviewed.
 
Emerging Therapies for Eosinophilic Gastrointestinal Diseases.
Peterson K., Safroneeva E., Schoepfer A., 2021/09. The journal of allergy and clinical immunology. In practice, 9 (9) pp. 3276-3281. Peer-reviewed.
 
Gastrointestinal quality of life before and short- and long-term after Roux-en-Y gastric bypass for severe obesity.
Waridel C., Schoepfer A., Suter M., 2021/09. Surgery for obesity and related diseases, 17 (9) pp. 1583-1590. Peer-reviewed.
Guide pratique de la prise en charge des patients avec maladies inflammatoires chroniques de l’intestin pour les médecins généralistes [A practical guide to chronic inflammatory bowel disease]
Salvador Nunes L., Greuter T., Henchoz S., Schoepfer A., 2021/09/01. Revue medicale suisse, 17 (748) pp. 1448-1452. Peer-reviewed.
Impact du Covid-19 sur la gastroentérologie et l’hépatologie.
Schoepfer A., Frossard J.L., MORADPOUR D., 2021/09/01. Revue medicale suisse, 17 (748) p. 1435. Peer-reviewed.
 
The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients.
Roth R., Vavricka S., Scharl M., Schreiner P., Safroneeva E., Greuter T., Zeitz J., Misselwitz B., Schoepfer A., Barry M.P. et al., 2021/09. United European gastroenterology journal, 9 (7) pp. 773-780. Peer-reviewed.
Crohn's versus Cancer: Comparison of Functional and Surgical Outcomes after Right-Sided Resections.
Grass F., Zhu E., Brunel C., Hübner M., Schoepfer A., Demartines N., Hahnloser D., 2021/06. Digestive diseases, 39 (2) pp. 106-112. Peer-reviewed.
Long-term outcome of surgery for perianal Crohn's fistula
Schaad M, Hahnloser D, Schoepfer A, Rossel J -B, Rogler G, 2021/05/28. dans Abstracts of the 108th Annual Swiss Congress of Surgery, British Journal of Surgery. Peer-reviewed.
Transplantation de microbiote fécal : de l’évidence aux réalités du terrain [Fecal microbiota transplantation: from the evidence to the realty of the field]
Ballif A., Gerber S., Carrez L., Audry M., Sadeghipour F., Mitouassiwou A., Croxatto A., Opota O., Prod'hom G., Henchoz S. et al., 2021/04/14. Revue medicale suisse, 17 (734) pp. 726-731. Peer-reviewed.
 
Emerging treatment options for extraintestinal manifestations in IBD.
Greuter T., Rieder F., Kucharzik T., Peyrin-Biroulet L., Schoepfer A.M., Rubin D.T., Vavricka S.R., 2021/04. Gut, 70 (4) pp. 796-802. Peer-reviewed.
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis.
Dellon E.S., Collins M.H., Rothenberg M.E., Assouline-Dayan Y., Evans L., Gupta S., Schoepfer A., Straumann A., Safroneeva E., Rodriguez C. et al., 2021/03. Clinical gastroenterology and hepatology, 19 (3) pp. 473-483.e17. Peer-reviewed.
Gastroentérologie et hépatologie [Advances in gastroenterology and hepatology 2020]
Artru F., Fraga M., Godat S., Schoepfer A.M., Moradpour D., 2021/01/13. Revue medicale suisse, 17 (720-1) pp. 29-32. Peer-reviewed.
 
Benefit of radiofrequency ablation after widespread endoscopic resection of neoplastic Barrett's esophagus in daily practice
Godat Sébastien, 2021. Annals of Gastroenterology.
 
Food-induced immediate response of the esophagus-A newly identified syndrome in patients with eosinophilic esophagitis.
Biedermann L., Holbreich M., Atkins D., Chehade M., Dellon E.S., Furuta G.T., Hirano I., Gonsalves N., Greuter T., Gupta S. et al., 2021/01. Allergy, 76 (1) pp. 339-347. Peer-reviewed.
 
Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland.
Aksan A., Schoepfer A., Juillerat P., Vavricka S., Bettencourt M., Ramirez de Arellano A., Gavata S., Morin N., Valentine W.J., Hunt B., 2021/01. Advances in therapy, 38 (1) pp. 660-677. Peer-reviewed.
 
Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic Esophagitis.
Schoepfer A.M., Schürmann C., Trelle S., Zwahlen M., Ma C., Chehade M., Dellon E.S., Jairath V., Feagan B.G., Bredenoord A.J. et al., 2021. International archives of allergy and immunology, 182 (12) pp. 1169-1193. Peer-reviewed.
 
Dilation Modifies Association Between Symptoms and Esophageal Eosinophilia in Adult Patients With Eosinophilic Esophagitis.
Safroneeva E., Cotton C.C., Schoepfer A.M., Zwahlen M., Woosley J.T., Dellon E.S., 2020/12. The American journal of gastroenterology, 115 (12) pp. 2098-2102. Peer-reviewed.
 
Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.
Greuter T., Porchet F., Braga-Neto M.B., Rossel J.B., Biedermann L., Schreiner P., Scharl M., Schoepfer A.M., Safroneeva E., Straumann A. et al., 2020/12. United European gastroenterology journal, 8 (10) pp. 1196-1207. Peer-reviewed.
 
Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
Straumann A., Lucendo A.J., Miehlke S., Vieth M., Schlag C., Biedermann L., Vaquero C.S., Ciriza de Los Rios C., Schmoecker C., Madisch A. et al., 2020/11. Gastroenterology, 159 (5) pp. 1672-1685.e5. Peer-reviewed.
 
Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis.
Schreiner P., Meissgeier S., Safroneeva E., Greuter T., Rogler G., Schoepfer A., Simon D., Simon H.U., Biedermann L., Straumann A., 2020/10. Clinical gastroenterology and hepatology, 18 (11) pp. 2456-2462. Peer-reviewed.
 
Total and activity-induced energy expenditure measured during a year in children with inflammatory bowel disease in clinical remission remain lower than in healthy controls
Godin Jean-Philippe, Martin Francois-Pierre, Breton Isabelle, Schoepfer Alain, Nydegger Andreas, 2020/10. Clinical Nutrition, 39 (10) pp. 3147-3152. Peer-reviewed.
Insuffisance pancréatique : insuffisance diagnostique ? [Pancreatic insufficiency : diagnostic insufficiency ?]
Dombre V., Schoepfer A., Marx M., Robert M., Godat S., David G., 2020/09/02. Revue medicale suisse, 16 (704) pp. 1564-1568. Peer-reviewed.
 
Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study.
Cernoch P.S., Fournier N., Zeitz J., Scharl M., Morell B., Greuter T., Schreiner P., Misselwitz B., Safroneeva E., Schoepfer A.M. et al., 2020/09. Digestive diseases and sciences, 65 (9) pp. 2654-2663. Peer-reviewed.
 
Follow-Up Ileocolonoscopy Is Underused in Crohn's Disease Patients after Ileocecal Resection despite Higher Total and Inpatient Health-Care Costs Compared to Controls.
Vavricka S.R., Greuter T., Brüngger B., Blozik E., Celeiro J., Schoepfer A.M., Bähler C., 2020/08. Inflammatory intestinal diseases, 5 (3) pp. 100-108. Peer-reviewed.
Reflux gastro-œsophagien chez le ­patient obèse ; prise en charge actuelle [Gastroesophageal reflux disease in obese patients ; current management]
Khallouf J., Figueiredo S.G., Demartines N., Schoepfer A., Schäfer M., Mantziari S., 2020/07/01. Revue medicale suisse, 16 (699) pp. 1287-1291. Peer-reviewed.
 
Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know.
Schreiner P., Mueller N.J., Fehr J., Maillard M.H., Brand S., Michetti P., Schoepfer A., Restellini S., Vulliemoz M., Vavricka S.R. et al., 2020/06/27. Journal of Crohn's & colitis, 15 (2) pp. 316–325. Peer-reviewed.
 
Editorial: fluticasone propionate orally disintegrating tablets-interesting concept but is it going anywhere? Authors' reply.
Hirano I., Safroneeva E., Roumet M.C., Comer G.M., Eagle G., Schoepfer A., Falk G.W., 2020/05. Alimentary pharmacology & therapeutics, 51 (10) pp. 990-991. Peer-reviewed.
 
Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis.
Hirano I., Safroneeva E., Roumet M.C., Comer G.M., Eagle G., Schoepfer A., Falk G.W., 2020/04. Alimentary pharmacology & therapeutics, 51 (8) pp. 750-759. Peer-reviewed.
 
Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.
Schoepfer A., Vavricka S.R., Brüngger B., Blozik E., Bähler C., 2020/03. European journal of gastroenterology & hepatology, 32 (3) pp. 350-357. Peer-reviewed.
Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.
Serra E.G., Schwerd T., Moutsianas L., Cavounidis A., Fachal L., Pandey S., Kammermeier J., Croft N.M., Posovszky C., Rodrigues A. et al., 2020/02/21. Nature communications, 11 (1) p. 995. Peer-reviewed.
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I., Dellon E.S., Hamilton J.D., Collins M.H., Peterson K., Chehade M., Schoepfer A.M., Safroneeva E., Rothenberg M.E., Falk G.W. et al., 2020/01. Gastroenterology, 158 (1) pp. 111-122.e10. Peer-reviewed.
 
Management of the Elderly Inflammatory Bowel Disease Patient.
Hruz P., Juillerat P., Kullak-Ublick G.A., Schoepfer A.M., Mantzaris G.J., Rogler G., on behalf of Swiss IBDnet an official working group of the Swiss Society of Gastroenterology, 2020. Digestion, 101 Suppl 1 pp. 105-119. Peer-reviewed.
 
Systematic Assessment of Adult Patients' Satisfaction with Various Eosinophilic Esophagitis Therapies.
Safroneeva E., Hafner D., Kuehni C.E., Zwahlen M., Trelle S., Biedermann L., Greuter T., Vavricka S.R., Straumann A., Schoepfer A.M., 2020. International archives of allergy and immunology, 181 (3) pp. 211-220. Peer-reviewed.
 
Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update.
Burri E., Maillard M.H., Schoepfer A.M., Seibold F., Van Assche G., Rivière P., Laharie D., Manz M., Swiss IBDnet an official working group of the Swiss Society of Gastroenterology, 2020. Digestion, 101 Suppl 1 pp. 2-15. Peer-reviewed.
 
Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding.
Restellini S., Biedermann L., Hruz P., Mottet C., Moens A., Ferrante M., Schoepfer A.M., on behalf of Swiss IBDnet an official working group of the Swiss Society of Gastroenterology, 2020. Digestion, 101 Suppl 1 pp. 27-42. Peer-reviewed.
 
Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis.
Baehler C., Brüngger B., Blozik E., Vavricka S.R., Schoepfer A.M., 2019/10. Inflammatory intestinal diseases, 4 (4) pp. 144-153. Peer-reviewed.
 
Reply.
Greuter T., Schoepfer A.M., Straumann A., 2019/10. Clinical gastroenterology and hepatology, 17 (11) pp. 2385-2386. Peer-reviewed.
 
Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study.
Frei R., Fournier N., Zeitz J., Scharl M., Morell B., Greuter T., Schreiner P., Misselwitz B., Safroneeva E., Schoepfer A.M. et al., 2019/09/27. Journal of Crohn's & colitis, 13 (10) pp. 1292-1301. Peer-reviewed.
 
Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease.
Schoepfer A., Santos J., Fournier N., Schibli S., Spalinger J., Vavricka S., Safroneeva E., Aslan N., Rogler G., Braegger C. et al., 2019/09/27. Journal of Crohn's & colitis, 13 (10) pp. 1334-1342. Peer-reviewed.
ABC des polypes coliques [Abecedary of colonic polyps]
Archanioti P., Bornand A., Sempoux C., Unger S., Schoepfer A., Robert M., David G., 2019/08/28. Revue medicale suisse, 15 (660) pp. 1483-1487. Peer-reviewed.
 
Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
Lucendo A.J., Miehlke S., Schlag C., Vieth M., von Arnim U., Molina-Infante J., Hartmann D., Bredenoord A.J., Ciriza de Los Rios C., Schubert S. et al., 2019/07. Gastroenterology, 157 (1) pp. 74-86.e15. Peer-reviewed.
 
Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis.
Schoepfer A.M., Hirano I., Coslovsky M., Roumet M.C., Zwahlen M., Kuehni C.E., Hafner D., Alexander J.A., Dellon E.S., Gonsalves N. et al., 2019/07. Clinical gastroenterology and hepatology, 17 (8) pp. 1477-1488.e10. Peer-reviewed.
 
The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy.
Hedin CRH, Vavricka S.R., Stagg A.J., Schoepfer A., Raine T., Puig L., Pleyer U., Navarini A., van der Meulen-de Jong A.E., Maul J. et al., 2019/04/26. Journal of Crohn's & colitis, 13 (5) pp. 541-554. Peer-reviewed.
 
Symptom-based patient-reported outcomes in adults with eosinophilic esophagitis: value for treatment monitoring and randomized controlled trial design.
Safroneeva E., Schoepfer A.M., 2019/04. Current opinion in allergy and clinical immunology, 19 (2) pp. 169-174. Peer-reviewed.
 
Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients.
Greuter T., Safroneeva E., Bussmann C., Biedermann L., Vavricka S.R., Katzka D.A., Schoepfer A.M., Straumann A., 2019/02. Clinical gastroenterology and hepatology, 17 (3) pp. 419-428.e6. Peer-reviewed.
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Hirano I., Collins M.H., Assouline-Dayan Y., Evans L., Gupta S., Schoepfer A.M., Straumann A., Safroneeva E., Grimm M., Smith H. et al., 2019/02. Gastroenterology, 156 (3) pp. 592-603.e10. Peer-reviewed.
 
Chronisch entzündliche Darmerkrankungen []
Schoepfer A., 2019/01. Therapeutische Umschau. Revue therapeutique, 75 (5) p. 253. Peer-reviewed.
 
Epidemiologie und sozio-ökonomische Aspekte der chronisch entzündlichen Darmerkrankungen in der Schweiz [Epidemiology and socio-economic aspects of chronic inflammatory bowel diseases in Switzerland]
Schoepfer A., Safroneeva E., 2019/01. Therapeutische Umschau. Revue therapeutique, 75 (5) pp. 255-259. Peer-reviewed.
 
Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study.
Scharl S., Barthel C., Rossel J.B., Biedermann L., Misselwitz B., Schoepfer A.M., Straumann A., Vavricka S.R., Rogler G., Scharl M. et al., 2019/01. The American journal of gastroenterology, 114 (1) pp. 116-126. Peer-reviewed.
 
Eosinophilic esophagitis: latest insights from diagnosis to therapy.
Schoepfer A., Blanchard C., Dawson H., Lucendo A., Mauro A., Ribi C., Safroneeva E., Savarino E.V., Penagini R., 2018/12. Annals of the New York Academy of Sciences, 1434 (1) pp. 84-93. Peer-reviewed.
 
Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course.
Greuter T., Piller A., Fournier N., Safroneeva E., Straumann A., Biedermann L., Godat S., Nydegger A., Scharl M., Rogler G. et al., 2018/11/28. Journal of Crohn's & colitis, 12 (12) pp. 1399-1409. Peer-reviewed.
 
Adults with eosinophilic oesophagitis identify symptoms and quality of life as the most important outcomes.
Safroneeva E., Balsiger L., Hafner D., Kuehni C.E., Zwahlen M., Trelle S., Godat S., Biedermann L., Greuter T., Vavricka S. et al., 2018/11. Alimentary pharmacology & therapeutics, 48 (10) pp. 1082-1090. Peer-reviewed.
 
Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review.
Ma C., van Rhijn B.D., Jairath V., Nguyen T.M., Parker C.E., Aceves S.S., Furuta G.T., Gupta S.K., Katzka D.A., Safroneeva E. et al., 2018/11. Clinical gastroenterology and hepatology, 16 (11) pp. 1714-1729.e3. Peer-reviewed.
 
Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.
Guilcher K., Fournier N., Schoepfer A., Schibli S., Spalinger J., Braegger C., Nydegger A., Swiss IBD Cohort Study, 2018/10. European journal of gastroenterology & hepatology, 30 (10) pp. 1159-1167. Peer-reviewed.
 
Patient-reported complementary and alternative medicine use in IBD: 10 years of observation among patients included in a national cohort
Pittet V., Aslan N., Fournier N., Decollogny A., Schoepfer A., Seibold F., Rodondi P.Y., 2018/10., 26th United European Gastroenterology Week, UEG 2018, Vienna pp. A227-A228 dans United European Gastroenterology Journal, Supl..
 
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference.
Dellon E.S., Liacouras C.A., Molina-Infante J., Furuta G.T., Spergel J.M., Zevit N., Spechler S.J., Attwood S.E., Straumann A., Aceves S.S. et al., 2018/10. Gastroenterology, 155 (4) pp. 1022-1033.e10. Peer-reviewed.
 
Ustekinumab – eine Standortbestimmung [Ustekinumab - Current position]
Siegmund B., Högenauer C., Novacek G., Petritsch W., Reinisch W., Schoepfer A., Schreiber S., Vavricka S., Bokemeyer B., für die IBD-Dach-Gruppe, 2018/09. Zeitschrift fur Gastroenterologie, 56 (9) pp. 1077-1086. Peer-reviewed.
 
Drainage des voies biliaires et du pancréas par échographie endoscopique : actualités [Endoscopic ultrasound - guided biliary and pancreatic drainage: an update]
Aslan N., Schoepfer A., Robert M., David G., Moschouri E., Galasso D., Godat S., 2018/08/29. Revue medicale suisse, 14 (616) pp. 1495-1498. Peer-reviewed.
 
Maladies fonctionnelles digestives: mise au point concernant la classification Rome IV [Functional gastrointestinal disorders: update on the Rome IV criteria]
Marx M., Maye H., Abdelrahman K., Hessler R., Moschouri E., Aslan N., Godat S., Nichita C., Wiesel P., Perez L. et al., 2018/08/29. Revue medicale suisse, 14 (616) pp. 1512-1516. Peer-reviewed.
 
Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
Schoepfer A., Vavricka S.R., Brüngger B., Reich O., Blozik E., Bähler C., 2018/08. European journal of gastroenterology & hepatology, 30 (8) pp. 868-875. Peer-reviewed.
 
Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study.
Parragi L., Fournier N., Zeitz J., Scharl M., Greuter T., Schreiner P., Misselwitz B., Safroneeva E., Schoepfer A.M., Vavricka S.R. et al., 2018/06/28. Journal of Crohn's & colitis, 12 (7) pp. 811-818. Peer-reviewed.
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
Godat S., Fournier N., Safroneeva E., Juillerat P., Nydegger A., Straumann A., Vavricka S., Biedermann L., Greuter T., Fraga M. et al., 2018/06. European journal of gastroenterology & hepatology, 30 (6) pp. 612-620. Peer-reviewed.
 
Evolution of percutaneous endoscopic gastrostomy from 2007 to 2016 in children at a tertiary center.
Zumsteg Sarah, Schoepfer Alain, Nydegger Andreas, 2018/05/24. dans Annual conference of the Swiss Society of Pediatrics (Lausanne).
 
Systematic analysis of the impact of diagnostic delay in pediatric versus adult onset Crohn’s disease
Santos Jessica, Schoepfer Alain, Nydegger Andreas, 2018/05/24. dans Annual conference of the Swiss Society of Pediatrics (Lausanne).
 
Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland
Guilcher Katharina, Fournier Nicolas, Schoepfer Alain, Schibli Susanne, Spalinger Johannes, Braegger Christian, Nydegger Andreas, 2018/05/09. dans Annual conference of ESPGHAN (Geneva).
 
Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS).
Safroneeva E., Saner C., Rossel J.B., Golay D., Pittet V., Godat S., Diem S., Aepli P., Sawatzki M., Borovicka J. et al., 2018/03. Inflammatory intestinal diseases, 2 (3) pp. 163-170. Peer-reviewed.
 
Eosinophilic Esophagitis: Relationship of Subepithelial Eosinophilic Inflammation With Epithelial Histology, Endoscopy, Blood Eosinophils, and Symptoms.
Schoepfer A.M., Simko A., Bussmann C., Safroneeva E., Zwahlen M., Greuter T., Biedermann L., Vavricka S., Godat S., Reinhard A. et al., 2018/03. The American journal of gastroenterology, 113 (3) pp. 348-357. Peer-reviewed.
Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
Vavricka S.R., Galván J.A., Dawson H., Soltermann A., Biedermann L., Scharl M., Schoepfer A.M., Rogler G., Prinz Vavricka M.B., Terracciano L. et al., 2018/02/28. Journal of Crohn's & colitis, 12 (3) pp. 347-354. Peer-reviewed.
 
Patient-reported complementary and alternative medicine use in IBD: 10 years of observation among patients included in a national cohort
Pittet V, Aslan N, Fournier N, Decollogny A, Schoepfer A, Seibold F, Rodondi P -Y, 2018/01/16., 13th ECCO Congress, Vienna 2018 pp. S401-S402 dans Journal of Crohn's and Colitis. Peer-reviewed, Oxford University Press (OUP).
 
Assessment of endoscopic Doppler to guide hemostasis in high risk peptic ulcer bleeding.
Kantowski M., Schoepfer A.M., Settmacher U., Stallmach A., Schmidt C., 2018. Scandinavian journal of gastroenterology, 53 (10-11) pp. 1311-1318. Peer-reviewed.
 
Latest Insights on the Relationship Between Symptoms and Biologic Findings in Adults with Eosinophilic Esophagitis.
Safroneeva E., Straumann A., Schoepfer A.M., 2018/01. Gastrointestinal endoscopy clinics of North America, 28 (1) pp. 35-45. Peer-reviewed.
Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients.
Greuter T., Franc Y., Kaelin M., Schoepfer A.M., Schreiner P., Zeitz J., Scharl M., Misselwitz B., Straumann A., Vavricka S.R. et al., 2018. Therapeutic advances in gastroenterology, 11 pp. 1756283X18757715. Peer-reviewed.
 
Pharmacologic Treatment of Eosinophilic Esophagitis: An Update.
Schoepfer A.M., Straumann A., Safroneeva E., 2018/01. Gastrointestinal endoscopy clinics of North America, 28 (1) pp. 77-88. Peer-reviewed.
Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).
Cheng K., Gupta S.K., Kantor S., Kuhl J.T., Aceves S.S., Bonis P.A., Capocelli K.E., Carpenter C., Chehade M., Collins M.H. et al., 2017/12/18. Translational science of rare diseases, 2 (3-4) pp. 141-155. Peer-reviewed.
 
Maladies vasculaires rares, mise en place d’un centre multidisciplinaire spécialisé au CHUV [Rare vascular diseases, building dedicated multidisciplinary specialized center]
Krieger C., Baud D., Bouchardy J., Christen-Zaech S., De Buys A., Deglise S., El Ezzi O., Fresa M., Hofer M., Hohl D. et al., 2017/12/06. Revue medicale suisse, 13 (586) pp. 2109-2115. Peer-reviewed.
Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014.
Bähler C., Vavricka S.R., Schoepfer A.M., Brüngger B., Reich O., 2017/12/02. BMC gastroenterology, 17 (1) p. 138. Peer-reviewed.
 
Eosinophile Oesophagitis
Vavricka S.R., Safroneeva E., Schoepfer A., 2017/11. Therapeutische Umschau. Revue therapeutique, 74 (6) pp. 309-315. Peer-reviewed.
 
Eosinophilic esophagitis: What can we learn from Crohn's disease?
Molina-Infante J., Schoepfer A.M., Lucendo A.J., Dellon E.S., 2017/10. United European gastroenterology journal, 5 (6) pp. 762-772. Peer-reviewed.
 
Long-Term Treatment of Eosinophilic Esophagitis With Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept.
Greuter T., Bussmann C., Safroneeva E., Schoepfer A.M., Biedermann L., Vavricka S.R., Straumann A., 2017/10. The American journal of gastroenterology, 112 (10) pp. 1527-1535. Peer-reviewed.
Mise au point sur la rectocolite ulcéro-hémorragique en 2017 [Management of ulcerative colitis in 2017]
Moschouri E., Hessler R., Pittet V., Velin D., Conrad C., Hahnloser D., Gié O., Michetti P., Schoepfer A.M., Maillard M.H., 2017/08/30. Revue medicale suisse, 13 (572) pp. 1480-1486. Peer-reviewed.
 
Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland.
Bähler C., Schoepfer A.M., Vavricka S.R., Brüngger B., Reich O., 2017/08. European journal of gastroenterology & hepatology, 29 (8) pp. 916-925. Peer-reviewed.
Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.
Greuter T., Bertoldo F., Rechner R., Straumann A., Biedermann L., Zeitz J., Misselwitz B., Scharl M., Rogler G., Safroneeva E. et al., 2017/08. Journal of pediatric gastroenterology and nutrition, 65 (2) pp. 200-206. Peer-reviewed.
 
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
Vavricka S.R., Gubler M., Gantenbein C., Spoerri M., Froehlich F., Seibold F., Protic M., Michetti P., Straumann A., Fournier N. et al., 2017/07. Inflammatory bowel diseases, 23 (7) pp. 1174-1181. Peer-reviewed.
Hernie hiatale : prise en charge diagnostique et thérapeutique en 2017 [Hiatal hernia : current diagnostic and therapeutic management]
Allemann P., Guarnero V., Schoepfer A., Demartines N., Schäfer M., 2017/06/14. Revue medicale suisse, 13 (567) pp. 1248-1252. Peer-reviewed.
 
Eosinophilic esophagitis: unclear roles of IgE and eosinophils.
Blanchard C., Simon D., Schoepfer A., Straumann A., Simon H.U., 2017/05. Journal of internal medicine, 281 (5) pp. 448-457. Peer-reviewed.
 
Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding.
Marot A., Trépo E., Doerig C., Schoepfer A., Moreno C., Deltenre P., 2017/05. Liver international, 37 (5) pp. 707-716. Peer-reviewed.
 
Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults.
Lucendo A.J., Molina-Infante J., Arias Á., von Arnim U., Bredenoord A.J., Bussmann C., Amil Dias J., Bove M., González-Cervera J., Larsson H. et al., 2017/04. United European gastroenterology journal, 5 (3) pp. 335-358. Peer-reviewed.
 
The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity.
Greuter T., Schmidlin S., Lattmann J., Stotz M., Lehmann R., Zeitz J., Scharl M., Misselwitz B., Pohl D., Fried M. et al., 2017/03. Digestive and liver disease , 49 (3) pp. 268-272. Peer-reviewed.
 
Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease.
Schoepfer A.M., Vavricka S., Safroneeva E., Fournier N., Manser C., Frei P., Deltenre P., Rogler G., Straumann A., Ezri J. et al., 2017/02. Journal of pediatric gastroenterology and nutrition, 64 (2) pp. 245-247. Peer-reviewed.
Current concepts in eosinophilic esophagitis.
Simon D., Straumann A., Schoepfer A.M., Simon H.U., 2017. Allergo journal international, 26 (7) pp. 258-266. Peer-reviewed.
 
Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis.
Vicari A.P., Schoepfer A.M., Meresse B., Goffin L., Léger O., Josserand S., Guégan N., Yousefi S., Straumann A., Cerf-Bensussan N. et al., 2017. mAbs, 9 (6) pp. 927-944. Peer-reviewed.
 
Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
Fraga M., Fournier N., Safroneeva E., Pittet V., Godat S., Straumann A., Nydegger A., Vavricka S.R., Moradpour D., Schoepfer A.M. et al., 2017/01. European journal of gastroenterology & hepatology, 29 (1) pp. 91-97. Peer-reviewed.
Comparison of different biopsy forceps models for tissue sampling in eosinophilic esophagitis.
Bussmann C., Schoepfer A.M., Safroneeva E., Haas N., Godat S., Sempoux C., Simon H.U., Straumann A., 2016/12. Endoscopy, 48 (12) pp. 1069-1075. Peer-reviewed.
 
Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
Protic M., Schoepfer A., Yawalkar N., Vavricka S., Seibold F., 2016/12. Scandinavian journal of gastroenterology, 51 (12) pp. 1482-1488. Peer-reviewed.
 
Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders.
Dellon E.S., Collins M.H., Bonis P.A., Leung J., Capocelli K.E., Dohil R., Falk G.W., Furuta G.T., Menard-Katcher C., Gupta S.K. et al., 2016/12. Clinical gastroenterology and hepatology, 14 (12) pp. 1842-1844. Peer-reviewed.
 
Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease.
Mottet C., Schoepfer A.M., Juillerat P., Cosnes J., Froehlich F., Kessler-Brondolo V., Seibold F., Rogler G., Vavricka S.R., Michetti P., 2016/11. Inflammatory bowel diseases, 22 (11) pp. 2733-2747. Peer-reviewed.
 
How to measure disease activity in eosinophilic esophagitis.
Schoepfer A., Safroneeva E., Straumann A., 2016/11. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 29 (8) pp. 959-966. Peer-reviewed.
 
Celiac disease diagnosis still significantly delayed - Doctor's but not patients' delay responsive for the increased total delay in women.
Vavricka S.R., Vadasz N., Stotz M., Lehmann R., Studerus D., Greuter T., Frei P., Zeitz J., Scharl M., Misselwitz B. et al., 2016/10. Digestive and liver disease, 48 (10) pp. 1148-1154. Peer-reviewed.
 
Eosinophilic esophagitis: current perspectives from diagnosis to management.
Moawad F.J., Cheng E., Schoepfer A., Al-Haddad S., Bellizzi A.M., Dawson H., El-Zimaity H., Guindi M., Penagini R., Safrooneva E. et al., 2016/09. Annals of the New York Academy of Sciences, 1380 (1) pp. 204-217. Peer-reviewed.
 
Gastroentérite à éosinophiles [Eosinophilic gastrointestinal disorders]
Burgmann K., Brunel C., Sempoux C., Ribi C., Godat S., Moradpour D., Schoepfer A.M., 2016/08/31. Revue medicale suisse, 13 (528) pp. 1430-1433. Peer-reviewed.
 
A new eosinophilic esophagitis (EoE)-like disease without tissue eosinophilia found in EoE families.
Straumann A., Blanchard C., Radonjic-Hoesli S., Bussmann Ch, Hruz P., Safroneeva E., Simon D., Schoepfer A.M., Simon H.U., 2016/06. Allergy, 71 (6) pp. 889-900. Peer-reviewed.
 
Eosinophilic esophagitis is characterized by a non-IgE-mediated food hypersensitivity.
Simon D., Cianferoni A., Spergel J.M., Aceves S., Holbreich M., Venter C., Rothenberg M.E., Terreehorst I., Muraro A., Lucendo A.J. et al., 2016/05. Allergy, 71 (5) pp. 611-620. Peer-reviewed.
 
Diagnostischer Nutzen von Calprotectin im klinischen Alltag
Burri Emanuel, Beglinger Christoph, Biedermann Lukas, Michetti Pierre, Nydegger Andreas, Schoepfer Alain, Seibold Frank, Vavricka Stefan, Rogler Gerhard, 2016/01/20. Swiss Medical Forum, 16 (3) pp. 68-73.
 
Eosinophilic Esophagitis: Impact of Latest Insights Into Pathophysiology on Therapeutic Strategies.
Schoepfer A., Safroneeva E., Straumann A., 2016. Digestive Diseases (basel, Switzerland), 34 (5) pp. 462-468. Peer-reviewed.
 
Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists.
Vavricka S.R., Sulz M.C., Degen L., Rechner R., Manz M., Biedermann L., Beglinger C., Peter S., Safroneeva E., Rogler G. et al., 2016. Endoscopy, 48 (3) pp. 256-262. Peer-reviewed.
 
Patient-Reported Outcomes in Eosinophilic Esophagitis and Achalasia.
Schoepfer A., Straumann A., Safroneeva E., 2016. Current Treatment Options In Gastroenterology, 14 (1) pp. 51-60. Peer-reviewed.
 
Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort.
Alatri A., Schoepfer A., Fournier N., Engelberger R.P., Safroneeva E., Vavricka S., Biedermann L., Calanca L., Mazzolai L., Swiss IBD Cohort Study Group, 2016. Scandinavian Journal of Gastroenterology, 51 (10) pp. 1200-1205. Peer-reviewed.
 
Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis.
Molina-Infante J., Bredenoord A.J., Cheng E., Dellon E.S., Furuta G.T., Gupta S.K., Hirano I., Katzka D.A., Moawad F.J., Rothenberg M.E. et al., 2016. Gut, 65 (3) pp. 524-531. Peer-reviewed.
 
Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?
Mueller R., Ziade F., Pittet V., Fournier N., Ezri J., Schoepfer A., Schibli S., Spalinger J., Braegger C., Nydegger A. et al., 2016. Journal of Crohn's and Colitis, 10 (3) pp. 269-276. Peer-reviewed.
 
Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis.
Safroneeva E., Straumann A., Coslovsky M., Zwahlen M., Kuehni C.E., Panczak R., Haas N.A., Alexander J.A., Dellon E.S., Gonsalves N. et al., 2016. Gastroenterology, 150 (3) pp. 581-590.e4. Peer-reviewed.
 
Therapy: Positioning of dilation in eosinophilic oesophagitis.
Straumann A., Schoepfer A., 2016. Nature Reviews. Gastroenterology and Hepatology, 13 (4) pp. 192-194. Peer-reviewed.
 
Escalating incidence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 1993-2013: a population-based study.
Giriens B., Yan P., Safroneeva E., Zwahlen M., Reinhard A., Nydegger A., Vavricka S., Sempoux C., Straumann A., Schoepfer A.M., 2015/12. Allergy, 70 (12) pp. 1633-1639. Peer-reviewed.
 
Traitements chirurgicaux des maladies fonctionnelles oesogastriques [Surgical treatment of gastroesophageal diseases].
Winiker M., Schoepfer A., Demartines N., Allemann P., 2015/06. Revue Médicale Suisse, 11 (479) pp. 1351-1356. Peer-reviewed.
 
Characteristics of non-responders to self-reported questionnaires in a large inflammatory bowel disease cohort study.
Multone E., Vader J.P., Mottet C., Schoepfer A., Fournier N., Burnand B., Michetti P., Pittet V., 2015. Scandinavian Journal of Gastroenterology, 50 (11) pp. 1348-1356.
 
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
Vavricka S.R., Rogler G., Gantenbein C., Spoerri M., Prinz Vavricka M., Navarini A.A., French L.E., Safroneeva E., Fournier N., Straumann A. et al., 2015. Inflammatory Bowel Diseases, 21 (8) pp. 1794-1800. Peer-reviewed.
 
Diagnostic approach to eosinophilic oesophagitis: Pearls and pitfalls.
Schoepfer A., 2015. Best Practice and Research. Clinical Gastroenterology, 29 (5) pp. 783-792. Peer-reviewed.
 
Editorial: Serial Fecal Calprotectin and Lactoferrin Measurements for Early Diagnosis of Pouchitis After Proctocolectomy for Ulcerative Colitis: Is Pouchoscopy No Longer Needed?
Schoepfer A., Reinisch W., 2015. American Journal of Gastroenterology, 110 (6) pp. 888-890. Peer-reviewed.
 
Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity.
Safroneeva E., Coslovsky M., Kuehni C.E., Zwahlen M., Haas N.A., Panczak R., Taft T.H., Hirano I., Dellon E.S., Gonsalves N. et al., 2015. Alimentary Pharmacology and Therapeutics, 42 (8) pp. 1000-1010. Peer-reviewed.
Extraintestinal Manifestations of Inflammatory Bowel Disease.
Vavricka S.R., Schoepfer A., Scharl M., Lakatos P.L., Navarini A., Rogler G., 2015. Inflammatory Bowel Diseases, 21 (8) pp. 1982-1992. Peer-reviewed.
 
Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.
Safroneeva E., Vavricka S.R., Fournier N., Pittet V., Peyrin-Biroulet L., Straumann A., Rogler G., Schoepfer A.M., Swiss IBD Cohort Study Group, 2015. Alimentary Pharmacology and Therapeutics, 42 (8) pp. 977-989.
Prevalence and risk factors for therapy escalation in ulcerative colitis in the Swiss IBD Cohort Study
Safroneeva E., Vavricka S.R., Fournier N., Straumann A., Rogler G., Schoepfer A.M., 2015. Inflammatory Bowel Diseases, 21 (6) pp. 1348-1358. Peer-reviewed.
Prevalence and risk factors for thromboembolic complications in IBD patients
Schoepfer A., Alatri A., Fournier N., Safroneeva E., Calanca L., Mazzolai L., 2015., 10th Congress of ECCO-European Crohns & Colitis Organisation : Inflammatory bowel diseases. 18-21 February 2015, Barcelona, Spain pp. S178-S179 dans Journal of Crohn's & Colitis, Vol. 9 supl.1. Peer-reviewed.
Prevalence of extraintestinal manifestations in paediatric patients with Inflammatory Bowel Disease : results from the Swiss IBD Cohort Study
Vavricka S., Rechner R., Fournier N., Rogler G., Michetti P., Pittet V., Safroneeva E., Straumann A., Braegger C., Nydegger A. et al., 2015., 10th Congress of ECCO-European Crohns & Colitis Organisation : Inflammatory bowel diseases. 18-21 February 2015, Barcelona, Spain pp. S197-S197 dans Journal of Crohn's & Colitis ; vol. 9 supl. 1. Peer-reviewed.
 
Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn's disease: is colonoscopic surveillance no longer needed?
Schoepfer A.M., Lewis J.D., 2015. Gastroenterology, 148 (5) pp. 889-892.
 
Stenting after severe iatrogenic submucosal dissection in a patient with newly diagnosed eosinophilic esophagitis.
Sawatzki M., Schoepfer A., Borovicka J., Meyenberger C., Frei R., 2015. Gastrointestinal Endoscopy, 81 (6) pp. 1499-1501. Peer-reviewed.
 
Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.
Safroneeva E., Vavricka S., Fournier N., Seibold F., Mottet C., Nydegger A., Ezri J., Straumann A., Rogler G., Schoepfer A.M. et al., 2015. Alimentary Pharmacology and Therapeutics, 42 (5) pp. 540-548. Peer-reviewed.
Systematic evaluation of clinical predictors of aggressive ulcerative colitis
Vavricka S., Reinisch F., Fournier N., Pittet V., Safroneeva E., Scharl M., Michetti P., Rogler G., Schoepfer A., 2015., 10th Congress of ECCO-European Crohns & Colitis Organisation : Inflammatory bowel diseases. 18-21 February 2015, Barcelona, Spain pp. S140-S141 dans Journal of Crohn's & Colitis ; vol. 9 supl. 1. Peer-reviewed.
 
The 'Red Flag Instrument' for Early Detection of Crohn's Disease: Is it ready for Clinical Practice?
Schoepfer A., Vavricka S., 2015. Journal of Crohn's and Colitis, 9 (8) pp. 597-598. Peer-reviewed.
Therapie der CED bei Steroidversagen : Immunsuppressiva oder Biologika? [Therapy of steroid resistant inflammatory bowel disease Immunomodulators or biologicals?]
Manz M., Schoepfer A.M., 2014/12. coloproctology, 36 (6) pp. 433-438.
 
Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort
Hiroz P., Vavricka S.R., Fournier N., Safroneeva E., Pittet V., Rogler G., Schoepfer A.M., Swiss Inflammatory Bowel Diseases Cohort Study Group, 2014/10. Scandinavian Journal of Gastroenterology, 49 (10) pp. 1207-1218. Peer-reviewed.
 
Activity assessment of eosinophilic esophagitis.
Schoepfer A., Safroneeva E., 2014. Digestive Diseases, 32 (1-2) pp. 98-101. Peer-reviewed.
 
Actualités en gastroentérologie et hépatologie [Highlights in gastroenterology and hepatology 2013].
Hessler R., Godat S., Fraga M., Burgmann K., Doerig C., Deltenre P., Schoepfer A., 2014. Revue Médicale Suisse, 10 (412-413) pp. 41-44.
 
Addressing current treatment challenges in Crohn's disease in real life: A physician's survey.
Vavricka S.R., Radivojevic S., Manser C.N., Frei P., Burri E., Fried M., Schoepfer A., Peyrin-Biroulet L., Michetti P., Rogler G. et al., 2014. Digestive and Liver Disease, 46 (12) pp. 1066-1071. Peer-reviewed.
AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be.
Gisler V., Kraus D., Nemeth J., Lecompte M.T., Merz L., Stoeckle M., Schmid P., Bernasconi E., Weber R., Cavassini M. et al., 2014. Journal of the International Aids Society, 17 (4 Suppl 3) p. 19621. Peer-reviewed.
 
Akute Diarrhoe [Acute diarrhea].
Burgmann K., Schoepfer A., 2014. Therapeutische Umschau. Revue Therapeutique, 71 (9) pp. 529-535. Peer-reviewed.
 
Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.
Maillard M.H., Bortolotti M., Vader J.P., Mottet C., Schoepfer A., Gonvers J.J., Burnand B., Froehlich F., Michetti P., Pittet V. et al., 2014. Journal of Crohn's and Colitis, 8 (8) pp. 825-834.
 
Colites microscopiques--quoi de neuf ? [Microscopic colitis: update 2014].
Burgmann K., Fraga M., Schoepfer A.M., Yun P., 2014. Revue Médicale Suisse, 10 (440) pp. 1586, 1588-1586, 1590.
 
Commentary: the proton pump inhibitor test - does it have a role in eosinophilic oesophagitis? Authors' reply.
Moawad F.J., Schoepfer A.M., 2014. Alimentary Pharmacology and Therapeutics, 39 (8) pp. 897-898.
Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis.
Schoepfer A.M., Straumann A., Panczak R., Coslovsky M., Kuehni C.E., Maurer E., Haas N.A., Romero Y., Hirano I., Alexander J.A. et al., 2014. Gastroenterology, 147 (6) pp. 1255-1266.e21.
 
EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy.
Muraro A., Werfel T., Hoffmann-Sommergruber K., Roberts G., Beyer K., Bindslev-Jensen C., Cardona V., Dubois A., duToit G., Eigenmann P. et al., 2014. Allergy, 69 (8) pp. 1008-1025. Peer-reviewed.
 
Eosinophilic esophagitis: overview of clinical management.
Schoepfer A.M., Hirano I., Katzka D.A., 2014. Gastroenterology Clinics of North America, 43 (2) pp. 329-344. Peer-reviewed.
 
Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings.
Moawad F.J., Schoepfer A.M., Safroneeva E., Ally M.R., Chen Y.J., Maydonovitch C.L., Wong R.K., 2014. Alimentary Pharmacology and Therapeutics, 39 (6) pp. 603-608. Peer-reviewed.
 
High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients.
Vavricka S.R., Rogler G., Maetzler S., Misselwitz B., Safroneeva E., Frei P., Manser C.N., Biedermann L., Fried M., Higgins P. et al., 2014. Journal of Crohn's and Colitis, 8 (3) pp. 191-199. Peer-reviewed.
 
Late biliary complications in human alveolar echinococcosis are associated with high mortality.
Frei P., Misselwitz B., Prakash M.K., Schoepfer A.M., Prinz Vavricka B.M., Müllhaupt B., Fried M., Lehmann K., Ammann R.W., Vavricka S.R., 2014. World Journal of Gastroenterology, 20 (19) pp. 5881-5888. Peer-reviewed.
 
Monitoring Disease Activity and Progression in Crohn's Disease. A Swiss Perspective on the IBD Ahead 'Optimised Monitoring' Recommendations.
Sauter B., Beglinger C., Girardin M., Macpherson A., Michetti P., Schoepfer A., Seibold F., Vavricka S.R., Rogler G., 2014. Digestion, 89 (4) pp. 299-309. Peer-reviewed.
 
Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss Inflammatory Bowel Disease Cohort
Violi N.V., Vietti Violi N., Schoepfer A.M., Fournier N., Guiu B., Bize P., Denys A., Swiss Inflammatory Bowel Disease Cohort Study Group, 2014. Ajr. American Journal of Roentgenology, 203 (1) pp. 62-69. Peer-reviewed.
 
Reply.
Schoepfer A., Straumann A., 2014. Gastroenterology, 146 (5) pp. 1426-1427. Peer-reviewed.
 
Risk factors for repetitive ileocolic resection in patients with Crohn's disease: results of an observational cohort study.
Manser C.N., Frei P., Grandinetti T., Biedermann L., Mwinyi J., Vavricka S.R., Schoepfer A., Fried M., Rogler G., Investigators of the Swiss IBD Cohort Study, 2014. Inflammatory Bowel Diseases, 20 (9) pp. 1548-1554. Peer-reviewed.
 
Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
Schaffer T., Schoepfer A.M., Seibold F., Swiss IBD Cohort Study Group, 2014. Journal of Crohn's and Colitis, 8 (9) pp. 1125-1132. Peer-reviewed.
 
Steroid use in Crohn's disease.
Vavricka S.R., Schoepfer A.M., Scharl M., Rogler G., 2014. Drugs, 74 (3) pp. 313-324. Peer-reviewed.
 
The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.
Protic M., Seibold F., Schoepfer A., Radojicic Z., Juillerat P., Bojic D., Mwinyi J., Mottet C., Jojic N., Beglinger C. et al., 2014. Journal of Crohn's and Colitis, 8 (11) pp. 1427-1437. Peer-reviewed.
 
The gap between scientific evidence and clinical practice : 5-aminosalicylates are frequently used for the treatment of Crohn's disease
Schoepfer A.M., Bortolotti M., Pittet V., Mottet C., Gonvers J.J., Reich O., Fournier N., Vader J.P., Burnand B., Michetti P. et al., 2014. Alimentary Pharmacology and Therapeutics, 40 (8) pp. 930-937. Peer-reviewed.
 
Treatment of eosinophilic esophagitis by dilation.
Schoepfer A., 2014. Digestive Diseases, 32 (1-2) pp. 130-133.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University